Cogent Biosciences (COGT) Assets (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Assets data on file, last reported at $903.0 million in Q1 2026.

• On a quarterly basis, Assets rose 218.19% year-over-year to $903.0 million in Q1 2026; TTM through Mar 2026 was $903.0 million, a 218.19% increase from a year earlier, with the FY2025 full-year figure at $937.6 million, up 185.94% from the prior year.
• Assets for Q1 2026 stood at $903.0 million, down from $937.6 million in the prior quarter.
• Over the last five years, Assets for COGT reached as high as $937.6 million in Q4 2025 and fell as low as $206.9 million in Q1 2022.
• Historically, Assets has averaged $410.2 million across 5 years, with a median of $355.4 million in 2023.
• Across the five-year window, Assets plunged 40.39% in 2025 and surged 218.19% in 2026, its largest moves.
• Year by year, Assets stood at $300.8 million in 2022, then climbed by 4.2% to $313.4 million in 2023, then gained by 4.61% to $327.9 million in 2024, then surged by 185.94% to $937.6 million in 2025, then declined by 3.69% to $903.0 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $903.0 million in Q1 2026, $937.6 million in Q4 2025, and $425.9 million in Q3 2025.